Amendola B E, Lamm F R, Markoe A M, Karlsson U L, Shields J, Shields C L, Augsburger J, Brady L W, Woodleigh R, Miller C
Radiation Oncology Department, Hahnemann University Hospital, Philadelphia.
Cancer. 1990 Jul 1;66(1):21-6. doi: 10.1002/1097-0142(19900701)66:1<21::aid-cncr2820660105>3.0.co;2-g.
This is a retrospective review of treatment results in 63 children with retinoblastoma (RB) who received therapeutic irradiation from January 1975 to June 1988. Patient ages ranged from birth to 5 years with a mean age of 12.5 months. Three treatment groups were identified. In Group A, episcleral plaque was the only irradiation modality. In this group, 24 patients and 25 eyes with tumors of Reese-Ellsworth Stages I to III, and selected Stage VB tumors were irradiated using eye plaques. Twenty-two of 25 (88%) eyes are without evidence of disease (NED), and all patients are alive. Two eyes were enucleated for recurrent RB. Two of 23 eyes developed minimal cataracts. In Group B, external-beam was the only irradiation modality. Twelve patients with 21 involved eyes comprise this group. Thirteen eyes received EBRT alone. Seventy-seven percent of 13 eyes have NED. Four eyes developed cataracts. Three of 13 eyes required enucleation for progression of disease; one of these was Stage IVA and two of them were Stage VA. For Group C, external-beam plus episcleral plaque was used. Twenty-seven patients and 51 eyes with advanced retinoblastoma were included in this group. Episcleral plaque was used in 29 eyes as a salvage procedure for recurrent RB, or in selected cases was used as a boost after initial external beam irradiation. Fifteen of 29 eyes (52%) remain with NED with useful vision, and nine developed cataracts. Enucleation was performed in 14 eyes for recurrent RB. The authors conclude that radiation therapy has a major role in the management of RB due to its ability to control even advanced disease, allowing preservation of vision in a significant number of patients.
这是一项对63例视网膜母细胞瘤(RB)患儿治疗结果的回顾性研究,这些患儿于1975年1月至1988年6月接受了放射治疗。患者年龄从出生到5岁不等,平均年龄为12.5个月。确定了三个治疗组。A组中,巩膜外斑块是唯一的放射治疗方式。在该组中,24例患者的25只眼患有Reese-Ellsworth I至III期肿瘤,以及部分选定的VB期肿瘤,使用眼部斑块进行放射治疗。25只眼中的22只(88%)无疾病证据(NED),所有患者均存活。2只眼因RB复发而被摘除眼球。23只眼中有2只出现轻微白内障。B组中,外照射是唯一的放射治疗方式。该组包括12例患者的21只受累眼。13只眼仅接受了外照射放疗(EBRT)。13只眼中的77%无疾病证据。4只眼出现白内障。13只眼中有3只因疾病进展而需要摘除眼球;其中1只为IVA期,2只为VA期。C组使用外照射加巩膜外斑块治疗。该组包括27例患者的51只晚期视网膜母细胞瘤眼。29只眼使用巩膜外斑块作为RB复发的挽救治疗方法,或在某些选定病例中作为初始外照射后的加强治疗。29只眼中有15只(52%)无疾病证据且保留有用视力,9只眼出现白内障。14只眼因RB复发而被摘除眼球。作者得出结论,放射治疗在RB的治疗中起主要作用,因为它甚至能够控制晚期疾病,使大量患者能够保留视力。